Indirect pulp capping

PreclinicalSmall molecule

UUniversity of Valencia

Indirect pulp capping is one of 6 small molecule programs targeting Indirect Pulp Cap. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Indirect Pulp CapUnknown status

Indirect Pulp CapPreclinical

Unknown status

Competition

Competitive Landscape

6 competitors in Indirect Pulp Cap

#DrugCompanyPhaseTrials

Biodentine

IIstanbul University

Phase 3

2 2

Calcium Hydroxide

MMansoura University

Preclinical

2 3

Mineral Trioxide Aggregate

JJordan University of Science and Technology

Preclinical

2 4

Silver Diamine Fluoride

TThe University of Hong Kong

Preclinical

1 5

Indirect pulp capping

UUniversity of Valencia

Preclinical

1 6

Theracal LC

PPostgraduate Institute of Dental Sciences Rohtak

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Indirect Pulp Cap1 trial

Indirect Pulp Capping With Biodentine and TheraCal LC in Permanent Mature Molars

Unknown status·UUniversity of Valencia·N/A·NCT03741816·212 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Indirect pulp capping. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Indirect pulp capping compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Indirect pulp capping. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Valencia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Valencia

Indirect pulp capping

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Indirect Pulp Cap1 trial

References

Drug Info

Quick Facts

Related News